GlobeNewswire

Talend Unveils Industry's First Cloud-Native, Apache Beam-Powered Streaming Data Application

Dela

Talend Data Streams Free Version for AWS Joins Talend's Suite of Persona-based, Cloud Applications that Help Liberate Data, Accelerating Time-to-Insight for Data Scientists & Engineers

REDWOOD CITY, Calif. and NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Talend (NASDAQ: TLND), a global leader in  cloud and  big data integration solutions, unveiled Talend Data Streams, a free, Amazon marketplace application that simplifies and accelerates ingestion of massive volumes and wide varieties of real-time data. Released today at Talend Connect US, the company's annual customer and partner conference taking place in New York, Talend Data Streams provides self-service access to real-time data for engineers, data scientists, data analysts and other ad hoc integrators. The AWS-based, single-user application will eventually become part of Talend's existing suite of persona-based, cloud applications that enable everyone to work with trusted data.  

"Innovative business insights don't happen in a vacuum. Successful data pioneers have shown that being data-driven is a 'team sport', meaning all employees need to be involved in collecting, shaping and improving the quality and trust in data," said Ashley Stirrup, CMO, Talend. "Talend Data Streams now extends that collaboration to include data scientists, data engineers and data analysts using a self-service, easy-to-use, intuitive application for collecting real-time data, so companies can move from imagination to innovation, faster."

A recent survey of more than 16,000 data professionals showed that the most common challenges to data science include: dirty data (36%), lack of management support for data science teams (27%), lack of clear direction to pursue with available data (22%), and overall access to or availability of data (22%). 1 Talend Data Streams helps overcome these challenges by allowing data scientists, engineers and other analysts to:

  • Jump-start data integration with a zero-install, management-free, web-based UI that has users up and running in minutes
  • Rapidly ingest massive volumes of disparate, streaming and cloud data without complexity
  • Accelerate pipeline development with a unique live-preview feature that displays changes in real-time
  • Break the legacy cycle and extend the life of all data pipelines with the un-paralleled portability across cloud platforms powered by Apache Beam.

Delivering Trusted Data

Data is the new currency in today's digital economy. However, the economics of data are broken: data volumes continue to double each year, while the number of data workers triples, yet IT budgets remain flat-making it impossible to keep pace with growing business demands for information. In parallel, it's becoming increasingly common for disparate business units to use their own tools to collect and integrate data, leading to more information silos, or 'shadow IT', which ultimately prevents companies from reaching their data-driven potential.

Cloud-based, big data streaming technologies play a key role in helping companies utilize the cloud to scale data-driven decision making, while ensuring their most valuable asset-data-is governed, trusted, managed and accessible to a variety of employees.

"Digital business demands a consistent approach to the management of security, privacy and process compliance across enterprises. This isn't possible when 'information islands' fail to observe the standards required to ensure quality and consistency," said Ciaran Dynes, SVP of Products, Talend. "Thus, businesses need a radically different data architecture to overcome today's broken data economics and effectively put more of their data to work. Talend's mission is to liberate data from legacy infrastructures and improve its availability, quality, performance and value using citizen collaboration and the cloud."

Talend Data Streams will join the other persona-based apps currently available in Talend Data Fabric, an open source-based integration platform that combines all Talend products into a common set of powerful, easy-to-use tools for real-time or batch, data or application integration. Talend's suite of integrated, cloud-based, self-service apps are optimized for worker productivity and digital transformation. Using Talend, business and IT can collaborate on data integration and governance tasks, easily share work between apps, orchestrate stewardship tasks, increase confidence in their data and put more data to work, faster.

To learn more about the full capabilities and benefits of Talend Data Streams, customers can register for one of the live webinars, "Put More Data to Work: Talend Spring '18," on Tuesday, May 22, 2018 from either 10:30 - 11:30 am BST or 10:00 - 11:00 am PT. For additional insights on the impact the cloud and big data streaming can have on business performance, visit the Talend blog.

Like this story? Tweet this: #Spring '18 release of Talend Data Fabric liberates data with new Apache Beam-powered, cloud app for data streaming #CloudFirst data-driven enterprise http://bit.ly/2Drjt8K

__________________________

 

1 Kaggle 2017 State of Data Science and Machine Learning  survey of over 16,000 data professionals (collected in August 2017).

Chris Taylor
Talend
408-674-1238
ctaylor@talend.com
 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Talend via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum